A prospective observational study of ocular findings in immune checkpoint inhibitor recipients

A prospective observational study of ocular findings in immune checkpoint inhibitor recipients - A prospective observational study of ocular findings in immune checkpoint inhibitor recipients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000045141

Enrollment

100

Registered

2021-08-13

Start date

2020-08-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Patients who have treatment of Immune check point inhibitors are seen by an ophthalmologist before and after the start of dosing. Follow-up will be performed 1 month after administration, every 2 mont

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Since August 1st in 2020, for the patient to start the administration of the agent of the immune checkpoint inhibitors in Keiyu hospital.

Exclusion criteria

Exclusion criteria: Exclude if there is a reason such as general condition that cannot be examined or examined by an ophthalmologist.

Design outcomes

Primary

Measure	Time frame
Frequency of ocular findings and how to treat them	—

Countries

Japan

Contacts

Public ContactHideko Akagi

Keiyu hospital Oncology

h-akagi@keiyu-hospital.com0452218181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026